BML-278 is a SIRT1 activator with an EC150 of 1 μM.BML-278 increases H3K9 methylation and inhibits H3K9 acetylation in parental and maternal prokaryotes, and can be used to improve early embryonic development.BML-278 induces cell cycle arrest in primary human mesenchymal stromal cells at the G1/S phase, and can be used to delay senescence.BML-278 reduces microtubule protein acetylation in U937 cells and increases mitochondrial density in mouse C2C12 myoblasts. BML-278 reduces microtubule protein acetylation in U937 cells and increases mitochondrial density in mouse C2C12 myoblasts.